GlassScriptPhysician profile
Nathan T Rich
NPI 1396778148
$14,329.41
in general payments reported to CMS, 2019-2025
42 companies · $2,602 in 2025
The $2,602 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2021: $24.09 · 2022: $452 · 2023: $1,384 · 2024: $9,704 · 2025: $2,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,395 · Food and Beverage: $3,838 · Long Term Medical Supply Or Device Loan: $2,165 · Honoraria: $1,200 · Education: $92.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,395.00 |
| Food and Beverage | $3,837.68 |
| Long Term Medical Supply Or Device Loan | $2,165.10 |
| Honoraria | $1,200.00 |
| Education | $92.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $6,219.51 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $2,602.60 | 2022-2025 | |
| Cornerstone Specialty Network LLC | $1,200.00 | 2023-2024 | |
| Daiichi Sankyo INC. | $603.93 | 2022-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $410.67 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $346.59 | 2019-2025 | |
| Emd Serono, INC. | $308.06 | 2023-2025 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $301.30 | 2022-2025 | Imfinzi, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $272.04 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $264.79 | 2022-2025 | Xtandi, Vyloy, Padcev |
| Janssen Biotech, INC. | $178.67 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $131.02 | 2022-2025 | Opdivo, Opdualag |
| Array Biopharma INC | $113.94 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Genmab U.S., INC. | $111.41 | 2023-2025 | Tivdak, Epkinly |
| Genzyme Corporation | $108.27 | 2024-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,970.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.